By Dean Seal


American depositary receipts of BeiGene jumped after the company said the first doses of its lymphocytic leukemia treatment Brukinsa have been administered to patients in Armenia and Nepal.

The stock was up 9% at $179 in premarket trading. Shares had fallen 9% year-to-date when the market closed Tuesday.

The oncology company said Wednesday morning that the initial dosing comes as part of a three-year collaboration with a health equity nonprofit, The Max Foundation, and its own nonprofit charitable foundation to provide access to medicine in low- and middle-income countries.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

03-13-24 0842ET